Posts Tagged ‘pulmonary embolism’

July 12th, 2012

Selections from Richard Lehman’s Literature Review: July 12th

This week’s topics include sex differences in the protective effect of statins, an action measure to lower BP among diabetics, a prediction tool for initial survivors of in-hospital cardiac arrest, the diagnosis and treatment of pulmonary embolism, an intervention to prevent medication errors after hospital discharge, and rehospitalization after acute MI.

March 26th, 2012

Rivaroxaban Found Safe and Effective for Pulmonary Embolism

In recent years rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF patients, and as additional therapy to conventional antiplatelet therapy in ACS patients. Now, a study presented at the American College of Cardiology meeting in Chicago and published simultaneously in […]

January 23rd, 2012

Selections from Richard Lehman’s Weekly Review: Week of January 23rd

This week’s topics include bridging antiplatelet therapy in patients undergoing CABG, cognitive and neurologic outcomes after CABG, using IV beta-adrenergic agonists
during acute respiratory distress syndrome, and pulmonary embolism risk in those admitted to the hospital for an auto-immune disorder.

March 22nd, 2011

AHA Releases New Recommendations for Management of Acute VTE

The AHA is offering new guidance for the management of patients with pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension. The scientific statement is published online in Circulation. In addition to advice about anticoagulant therapy, the statement offers extensive recommendations about the appropriate use of fibrinolytic agents, catheter-based and surgical interventions, and […]

December 4th, 2010

Rivaroxaban Found Safe and Effective for DVT

In the EINSTEIN-DVT noninferiority study, 3449 patients with acute DVT were randomized to receive open label oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months. The rate of recurrent VTE, the primary efficacy outcome, was lower with rivaroxaban treatment than with enoxaparin treatment, successfully demonstrating noninferiority for […]